We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
EMA首次批准Jascayd（nerandomilast）用于治疗特发性和进行性肺纤维化。优势为68.8 mL，死亡率降低43%。了解肺病学的突破。
